Display options
Cite
Xu H, Chen Y, Gu M, et al. Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer. Metabolites. 2021;11(11)doi: 10.3390/metabo11110765.
Xu, H., Chen, Y., Gu, M., Liu, C., Chen, Q., Zhan, M., & Wang, Z. (2021). Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer. Metabolites, 11(11), . https://doi.org/10.3390/metabo11110765
Xu, Huan, et al. "Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer." Metabolites vol. 11,11 (2021). doi: https://doi.org/10.3390/metabo11110765
Xu H, Chen Y, Gu M, Liu C, Chen Q, Zhan M, Wang Z. Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer. Metabolites. 2021 Nov 09;11(11). doi: 10.3390/metabo11110765. PMID: 34822423; PMCID: PMC8618281.
Copy Download .nbib Format: NLM
Share it on

Metabolites. 2021 Nov 09;11(11). doi: 10.3390/metabo11110765.

Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer.

Metabolites

Huan Xu, Yanbo Chen, Meng Gu, Chong Liu, Qi Chen, Ming Zhan, Zhong Wang

Affiliations

  1. Department of Urology, Shanghai Ninth People's Hospital, Shanghai 200011, China.

PMID: 34822423 PMCID: PMC8618281 DOI: 10.3390/metabo11110765

Abstract

Prostate cancer (PCa) is a carcinoma in which fatty acids are abundant. Fatty acid metabolism is rewired during PCa development. Although PCa can be treated with hormone therapy, after prolonged treatment, castration-resistant prostate cancer can develop and can lead to increased mortality. Changes to fatty acid metabolism occur systemically and locally in prostate cancer patients, and understanding these changes may lead to individualized treatments, especially in advanced, castration-resistant prostate cancers. The fatty acid metabolic changes are not merely reflective of oncogenic activity, but in many cases, these represent a critical factor in cancer initiation and development. In this review, we analyzed the literature regarding systemic changes to fatty acid metabolism in PCa patients and how these changes relate to obesity, diet, circulating metabolites, and peri-prostatic adipose tissue. We also analyzed cellular fatty acid metabolism in prostate cancer, including fatty acid uptake, de novo lipogenesis, fatty acid elongation, and oxidation. This review broadens our view of fatty acid switches in PCa and presents potential candidates for PCa treatment and diagnosis.

Keywords: castration-resistant prostate cancer; fatty acid; metabolic reprogramming; neuroendocrine prostate cancer

References

  1. Cancer Metab. 2021 Aug 3;9(1):29 - PubMed
  2. Mol Cell Proteomics. 2016 Jan;15(1):154-63 - PubMed
  3. Genes Dev. 2011 May 15;25(10):1041-51 - PubMed
  4. Biochim Biophys Acta. 2011 Jun;1807(6):726-34 - PubMed
  5. Magn Reson Med. 1997 Aug;38(2):311-21 - PubMed
  6. J Magn Reson Imaging. 2015 Sep;42(3):651-7 - PubMed
  7. PLoS One. 2011;6(11):e27970 - PubMed
  8. Cell Signal. 2019 Oct;62:109336 - PubMed
  9. Front Oncol. 2021 May 07;11:666320 - PubMed
  10. BMC Public Health. 2008 Jun 05;8:200 - PubMed
  11. Pharmacol Res. 2012 Jun;65(6):565-76 - PubMed
  12. JAMA Oncol. 2020 Feb 1;6(2):206-216 - PubMed
  13. Endocr Connect. 2015 Dec;4(4):R68-80 - PubMed
  14. Mol Cells. 2011 Apr;31(4):371-7 - PubMed
  15. Nat Rev Cancer. 2016 Nov;16(11):718-731 - PubMed
  16. Nat Rev Immunol. 2002 Aug;2(8):569-79 - PubMed
  17. Eur Urol. 2016 Oct;70(4):599-608 - PubMed
  18. Hepatology. 2018 Feb;67(2):662-675 - PubMed
  19. Cancer Prev Res (Phila). 2015 Jun;8(6):545-51 - PubMed
  20. J Clin Invest. 2007 Jul;117(7):1866-75 - PubMed
  21. BMC Cancer. 2017 Sep 6;17(1):631 - PubMed
  22. Biochem Cell Biol. 2013 Dec;91(6):361-8 - PubMed
  23. Front Pharmacol. 2021 Feb 12;12:626155 - PubMed
  24. Sci Transl Med. 2019 Feb 6;11(478): - PubMed
  25. Lipids Health Dis. 2011 Sep 14;10:159 - PubMed
  26. Sci Rep. 2019 Dec 12;9(1):18944 - PubMed
  27. Nutr Cancer. 2017 Feb-Mar;69(2):184-200 - PubMed
  28. Cancer Causes Control. 2006 Oct;17(8):989-1003 - PubMed
  29. J Urol. 2018 Feb;199(2):430-437 - PubMed
  30. World J Surg Oncol. 2015 Jul 31;13:231 - PubMed
  31. Prostate Cancer Prostatic Dis. 2006;9(3):230-4 - PubMed
  32. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2404-12 - PubMed
  33. Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):149-54 - PubMed
  34. Mol Oncol. 2020 Dec;14(12):3100-3120 - PubMed
  35. Cell Death Dis. 2018 Feb 14;9(2):228 - PubMed
  36. Nutr Rev. 2008 Sep;66(9):506-16 - PubMed
  37. BJU Int. 2012 Oct;110(7):980-6 - PubMed
  38. J Urol. 2007 Nov;178(5):1939-44; discussion 1945 - PubMed
  39. Int J Urol. 2010 Sep;17(9):776-82 - PubMed
  40. Nat Med. 2011 Oct 30;17(11):1498-503 - PubMed
  41. Exp Cell Res. 1999 Mar 15;247(2):399-409 - PubMed
  42. In Vitro Cell Dev Biol. 1991 Feb;27A(2):142-6 - PubMed
  43. J Nucl Med. 2008 Feb;49(2):327-34 - PubMed
  44. J Immunother Cancer. 2021 Mar;9(3): - PubMed
  45. Oncogene. 2021 Mar;40(10):1806-1820 - PubMed
  46. J Lipid Res. 2013 Jan;54(1):71-84 - PubMed
  47. AJR Am J Roentgenol. 2015 Jan;204(1):W43-7 - PubMed
  48. Prostate. 2018 Jun;78(9):639-645 - PubMed
  49. Prostate. 2014 Feb;74(3):326-35 - PubMed
  50. Obesity (Silver Spring). 2008 Jun;16(6):1261-9 - PubMed
  51. Oncogene. 2020 Apr;39(18):3666-3679 - PubMed
  52. Clin Cancer Res. 2012 Nov 1;18(21):5850-5 - PubMed
  53. Molecules. 2020 Apr 03;25(7): - PubMed
  54. Nat Genet. 2018 Feb;50(2):206-218 - PubMed
  55. Br J Cancer. 2010 Jan 19;102(2):403-13 - PubMed
  56. Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):29-58 - PubMed
  57. Clin Sci (Lond). 2017 Apr 1;131(7):595-607 - PubMed
  58. Phytomedicine. 2017 Oct 15;34:1-5 - PubMed
  59. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):167-71 - PubMed
  60. Sci Rep. 2017 Sep 11;7(1):11079 - PubMed
  61. Int J Food Sci Nutr. 2017 Feb;68(1):28-42 - PubMed
  62. Cancer Res. 2009 Oct 15;69(20):8133-40 - PubMed
  63. Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):490-8 - PubMed
  64. Oncogene. 2017 Jun 15;36(24):3359-3374 - PubMed
  65. Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3334-3339 - PubMed
  66. Br J Cancer. 2015 Dec 22;113(12):1712-9 - PubMed
  67. Immunity. 2020 Jul 14;53(1):187-203.e8 - PubMed
  68. Oncotarget. 2017 Aug 3;8(51):88537-88551 - PubMed
  69. Sci Rep. 2017 Jul 5;7(1):4630 - PubMed
  70. Prostate. 2005 Mar 1;62(4):316-21 - PubMed
  71. Adv Exp Med Biol. 2018;1096:117-133 - PubMed
  72. CA Cancer J Clin. 2021 Jan;71(1):7-33 - PubMed
  73. Sci Rep. 2016 Feb 11;6:20984 - PubMed
  74. BJU Int. 2003 May;91(7):716-20 - PubMed
  75. Urology. 2016 Dec;98:107-112 - PubMed
  76. Ann Epidemiol. 2019 Jan;29:16-22.e1 - PubMed
  77. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13): - PubMed
  78. J Urol. 2009 Oct;182(4):1621-7 - PubMed
  79. Mol Cell. 2010 Jul 30;39(2):171-83 - PubMed
  80. Cytokine. 2016 Sep;85:148-56 - PubMed
  81. Nat Protoc. 2020 Aug;15(8):2668-2704 - PubMed
  82. Science. 2017 Jan 6;355(6320):84-88 - PubMed
  83. Br J Cancer. 2020 Jan;122(1):4-22 - PubMed
  84. Nutrients. 2016 Oct 12;8(10): - PubMed
  85. Cancers (Basel). 2021 Aug 05;13(16): - PubMed
  86. Sci Rep. 2017 Mar 03;7:43771 - PubMed
  87. Eur Urol. 2009 Oct;56(4):594-605 - PubMed
  88. Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E4966-75 - PubMed
  89. Inflammation. 2009 Jun;32(3):202-10 - PubMed
  90. J Invest Dermatol. 2001 Aug;117(2):244-50 - PubMed
  91. Transl Androl Urol. 2015 Jun;4(3):365-80 - PubMed
  92. Aging Male. 2019 Jun;22(2):102-108 - PubMed
  93. Cancer Metab. 2016 Apr 01;4:6 - PubMed
  94. Cancer. 2007 Dec 15;110(12):2691-9 - PubMed
  95. J Bone Miner Res. 2014;29(5):1183-95 - PubMed
  96. Cancer Metab. 2021 Jan 29;9(1):9 - PubMed
  97. J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):853-859 - PubMed
  98. Curr Opin Urol. 2018 Jan;28(1):55-61 - PubMed
  99. J Mammary Gland Biol Neoplasia. 2009 Dec;14(4):381-6 - PubMed
  100. Nat Rev Urol. 2021 Sep;18(9):519-542 - PubMed
  101. Int J Cancer. 2019 Dec 15;145(12):3231-3243 - PubMed
  102. Sci Rep. 2020 Sep 29;10(1):15975 - PubMed
  103. Cancer Res. 2007 Feb 1;67(3):1262-9 - PubMed
  104. Front Oncol. 2021 Jul 27;11:719865 - PubMed
  105. Oncogene. 2017 Oct 26;36(43):6030-6040 - PubMed
  106. Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83 - PubMed
  107. Sci Rep. 2017 Sep 4;7(1):10304 - PubMed
  108. Nat Med. 2016 Mar;22(3):298-305 - PubMed
  109. BMC Med Inform Decis Mak. 2020 Sep 24;20(Suppl 9):223 - PubMed
  110. N Engl J Med. 2014 Sep 11;371(11):1028-38 - PubMed
  111. Cancer. 2003 Apr 1;97(7):1639-43 - PubMed
  112. Eur Urol. 2013 May;63(5):800-9 - PubMed
  113. Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E6965-E6973 - PubMed
  114. Curr Opin Biotechnol. 2017 Feb;43:34-40 - PubMed
  115. J Pathol. 2011 Jan;223(2):283-94 - PubMed
  116. World J Urol. 2010 Dec;28(6):699-704 - PubMed
  117. Sci Rep. 2017 Jun 16;7(1):3710 - PubMed
  118. J Exp Clin Cancer Res. 2012 Apr 02;31:32 - PubMed
  119. Nat Commun. 2019 Sep 25;10(1):4358 - PubMed
  120. Metabolism. 2014 Feb;63(2):283-95 - PubMed
  121. Cell Metab. 2008 Sep;8(3):224-36 - PubMed
  122. Mol Cancer Ther. 2010 Jun;9(6):1740-54 - PubMed
  123. Nutr Hosp. 2014 Oct 31;31(3):1012-9 - PubMed
  124. Eur Urol. 2007 Aug;52(2):331-43 - PubMed
  125. Cancer Res. 2021 Apr 1;81(7):1704-1718 - PubMed
  126. BJU Int. 2011 Jun;107(11):1775-9 - PubMed
  127. Clin Cancer Res. 2018 Sep 1;24(17):4309-4318 - PubMed
  128. Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1331-5 - PubMed
  129. Eur Urol. 2016 May;69(5):942-52 - PubMed
  130. Biochim Biophys Acta. 2013 Oct;1831(10):1518-32 - PubMed
  131. Radiographics. 2007 Jan-Feb;27(1):63-75; discussion 75-7 - PubMed
  132. Cancer Metastasis Rev. 2011 Dec;30(3-4):295-309 - PubMed
  133. BJU Int. 2018 May;121 Suppl 3:9-21 - PubMed
  134. Urol J. 2014 Sep 06;11(4):1793-9 - PubMed
  135. Mol Cancer Res. 2019 Apr;17(4):949-962 - PubMed
  136. Bladder Cancer. 2016 Oct 27;2(4):369-379 - PubMed
  137. Radiology. 2011 Oct;261(1):46-66 - PubMed
  138. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640 - PubMed
  139. Cancer Cell Int. 2021 Jul 3;21(1):339 - PubMed
  140. Dis Markers. 2020 Jun 18;2020:3904947 - PubMed
  141. Front Oncol. 2021 Mar 17;11:642229 - PubMed
  142. J Pharmacol Exp Ther. 2007 Sep;322(3):973-81 - PubMed
  143. DNA Cell Biol. 1994 Dec;13(12):1189-97 - PubMed
  144. Curr Opin Oncol. 2009 Sep;21(5):469-74 - PubMed

Publication Types